The effects of the nonsteroidal antiandrogen bicalutamide (Casodex TM ) and the luteinizing hormone releasing hormone agonist leuprolide depot (Procren Depot TM , Lupron Depot TM ) on serum prostate-specific antigen (PSA), acid phosphatase (ACP), and prostatic acid phosphatase (PAP) in patients with benign prostatic hyperplasia (BPH) were determined. Thirty patients with BPH were randomised to receive bicalutamide 50 mg orally once daily or a placebo for 24 weeks, followed by 24 weeks of follow-up (bicalutamide study). In another study 55 men were randomised between 3.75 mg leuprolide depot intramuscularly at every 28 days for 24 weeks or placebo injections (leuprolide study). In both studies blood sampling was performed at baseline, at week 12 at week 24 and 24 weeks after the end of therapy. Androgen suppression with bicalutamide 50 mg daily for 24 weeks resulted in a median of 56% reduction of PSA (P < 0.001 when compared to placebo). Acid phosphatase and PAP did not change. Leuprolide resulted in a median of 87% reduction of serum PSA (P < 0.001) and a 39% reduction of PAP (P ¼ 0.023), whereas ACP was unchanged. Both bicalutamide and leuprolide induced a pronounced decline in serum PSA in BPH patients. The studies suggest a stronger androgen suppressive effect of leuprolide than of bicalutamide, but this difference might largely be due to too low a dosage of bicalutamide. ACP and PAP were relatively insensitive to androgen suppression. Our study suggests a different degree of androgen suppression on PSA originating from benign tissue versus cancer tissue, and that the direction of this discrepancy might be different for various androgen suppressive regimens.
Introduction
In two prospective, placebo controlled studies of patients with benign prostatic hyperplasia (BPH) we assessed the effects of two forms of androgen suppression on prostatespecific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP). Because of side effects and high cost, BPH patients are nonroutinely treated with these drugs, and the results of our studies are of limited clinical interest for this patient group. However, nonsteroidal antiandrogens and luteinising hormone-releasing hormone (LHRH) agonists are competing hormonal regimens for the treatment of prostate cancer, and because there is a strong association between the relative fall in prostate-specific antigen PSA and outcome of treatment for individual patients with prostate cancer, 1,2 PSA is widely used as a surrogate response parameter to decide the relative effectiveness of various hormonal treatment regimens, and in dose ranging studies. 1, 3, 4 Our data are of interest in comparing the relative effectiveness of these two forms of androgen suppression, but must be interpreted along with corresponding results on prostate cancer patients. Furthermore, a similar PSA reduction cannot without reservation be equalled to similar effectiveness against prostate cancer. The fall in PSA may represent a direct result of a decline in tumour volume, but may also reflect a change in protein binding or cellular production of PSA, independently of the tumour burden, reflecting a biological effect of the agent on PSA production or excretion.
Most men receiving hormones as primary treatment of prostate cancer have a substantial PSA elevation, and the overwhelming reason for the subsequent PSA decline is the hormonal effect on prostate cancer tissue. However, following the introduction of less toxic hormonal treatment regimens for prostate cancer, more patients with moderately elevated PSA and small cancers might be treated, in whom a substantial part of the PSA response will be due to the effect of androgen suppression on PSA from benign prostatic tissue. 5 Data from the present study will help predict the degree of PSA decline that can be expected for these patients.
To the best of our knowledge, data on the effect of bicalutamide on PSA in BPH patients have not been published earlier, and there are limited data on the exact effect of LHRH agonists. 6 -8 The more unspecific prostate cancer markers ACP and PAP presently play a minimal role in the diagnosis and monitoring of prostate cancer, but are included in this report because there are conflicting reports as to how they are influenced by androgen deprivation. 7, 9 Patients and methods Both studies were approved by the local ethical committee. Study participants were recruited from August 1989 to June 1991 among consecutive patients being referred for assessment of BPH at our out-patient clinic. Following informed consent, and depending on time of entry, they were entered into the leuprolide study or the bicalutamide study and randomised in a double-blind fashion to receive either placebo or active drug. 10, 11 Basically, the same protocol was used for both studies. Main inclusion criteria were: symptoms of BPH prostate size larger that 30 ml by transrectal ultrasound planimetry, maximum urinary flow rate of less than 12 ml per second and maximum intravesical pressure greater than 70 cmH 2 O by pressureflow examination. All men had four negative prostate biopsy cores prior to entry, taken from each side of the central part of the prostate by the perineal route.
In the bicalutamide study the patients received 50 mg once daily orally of the nonsteroidal antiandrogen bicalutamide or placebo. In the leuprolide study they received intramuscular injection every 28 days of 3.75 mg of the LHRH agonist leuprolide depot or matched placebo injections. For both studies the treatment period was 24 weeks followed by 24 weeks of follow-up.
Blood samples were drawn at weeks 0, 12, 24 and 48. Serum samples for PSA analyses were stored at 720 C and serial analysed for PSA approximately 6 months after completion of the studies, using the Abbott IMX radioimmunoassay. ACP and PAP were analysed in the hospital routine, using a radioimmunoassay technique. Hospital reference values were 0 -4.7 U/l for ACP and 0 -1.7 U/l for PAP. We excluded PSA results of men who had undergone prostate manipulation (cystoscopy, biopsy or pressure flow examination) less than 14 days prior to blood sampling and ACP and PAP results of men who had undergone prostate manipulation less than three days prior to blood sampling.
Statistics
The changes in PSA, ACP or PAP for patients receiving bicalutamide or leuprolide were compared with changes in the corresponding placebo groups. The absolute values of PSA and change in PSA were skewed with a right-hand tail, whereas percentage change in PSA and absolute change in ACP and PAP had a symmetrical distribution. Non-parametric (median, quartiles, Mann -Whitney test for comparison of two groups and Wilcoxon test for matched pairs) and parametric statistics (t-tests) were used. A P-value of < 0.05 was required for considering a difference statistically significant.
Results

Prostate-specific antigen
Baseline patient characteristics and reasons for exclusion are summarised in Tables 1 and 2 . For patients receiving bicalutamide median per cent PSA decrease was 47% (interquartiles 34 -69%) after 12 weeks (P < 0.001) and 56% (interquartiles 31 -71%) after 24 weeks (P < 0.001). At week 48 PSA had returned to baseline ( Figure 1 ). There was no statistically significant change in PSA for placebo patients. Two out of 11 patients had a PSA decrease of 80% or more, but none had a PSA decrease of 90% or more after 3 months. 
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For patients receiving leuprolide median per cent decrease in PSA was 83% (interquartiles 65 to 88%) after 12 weeks (P < 0.001). From week 12 to week 24 PSA continued to decrease (P ¼ 0.003), and per cent PSA decrease reached a median of 87% (interquartiles 82 -94%) compared to baseline (Figure 1 ). At week 48, PSA was 17% lower than before treatment started, not reaching statistical significance (P ¼ 0.072). For placebo patients, PSA was stable during the treatment period. Absolute values of PSA throughout the studies are summarized in Tables 3 and 4 . Eleven out of 14 patients receiving leuprolide had a PSA decrease of at least 80% after 3 months, and six had a decrease of at least 90%.
ACP and PAP
In the bicalutamide study average values for ACP and PAP were unchanged, except for a statisically significant increase (P < 0.05) at week 48 for patients receiving bicalutamide as well as for patients receiving placebo (Table  3) . However, there was no statistically significant difference in the between group comparison (bicalutamide vs placebo). Four out of 13 men had a PAP decrease of at least 50% at 12 weeks, versus two out of 13 placebo patients.
ACP did not change for patients receiving leuprolide or corresponding placebo. Mean PAP decreased by 42% (s.e.m. 14%) and 39% (s.e.m. 16%) at weeks 12 and 24, respectively, being statistically significant at week 24 (P ¼ 0.023) compared to placebo (Table 4) . Nine out of 23 men obtained a PAP decrease of at least 50% at 12 weeks, versus six out of 24 placebo patients.
Discussion
Androgen suppression by bicalutamide using a dose of 50 mg daily resulted in a median decrease in PSA of 56% after 24 weeks (Figure 1) . The per cent change in PSA was the same in all PSA ranges. These results are compatible with those reported for the closely related antiandrogen flutamide, which was evaluated in a 24-week doseresponse study involving 372 BPH patients. 12 In that study the per cent decrease in PSA was 42%, 55% and 61% at daily dosages of 250 mg, 500 mg, respectively. In another study, 750 mg flutamide in BPH patients resulted in a 52% decrease in PSA after 5 months. 13 At the time when the present study was designed a dosage of 50 mg bicalutamide was supposed to be sufficient, but the recommended dose of bicalutamide in men with prostate cancer has later been increased to 150 mg daily. 4, 14 This dosage would probably have resulted in a more pronounced PSA decline, and possibly also a No studies have compared the degree of PSA suppression of bicalutamide on BPH patients versus prostate cancer patients. However, with the 50 mg dosage, the literature suggests an 85 -88% PSA decline among men with prostate cancer, 1 which is probably more than the 56% decline that we found on our study patients. Correspondingly, flutamide 750 mg daily decreases PSA by 87% 15 and by 85% 16 after 6 months and by 87% after 9 weeks 17 on men with prostate cancer, vs 61% found on men with BPH. 12 For historical reasons, a 3.75 mg dose of bicalutamide is used in Europe versus 7.5 mg in the United States. The two dosages are assumed to be pharmacologically and clinically equivalent. After 24 weeks' treatment with 3.75 mg leuprolide we found a median per cent decrease in PSA of 87% (Figure 2 ). This result is very similar to other reports of the effect of LHRH agonists on PSA in BPH patients. After 6 months' treatment, Matzkin et al 7 found an 85% decline in 17 patients and Weber et al 8 found an 83% decline in seven patients, whereas Levine et al found an average PSA decline of 93.7% after 6 months. 6 However, average baseline PSA in this study was relatively high, 11.5 ng/1, suggesting that the study population included some patients with prostate cancer. In the present study, which also included several patients with moderately elevated PSA at entry (Tables 3 and 4) , prostate biopsy was performed prior to entry, and in addition a chart review was performed 4 -6 y following completion of the studies, and one patient who had developed clinical prostate cancer at that time was excluded. Consequently, we feel confident that our results are based on a pure BPH population.
Leuprolide on patients with prostate cancer results in 96 -97% PSA decline in average after three months. 1 Like the nonsteroidal antiandrogens, LHRH agonists seem to induce a more pronounced suppression of PSA originating from cancer tissue than of PSA of benign origin. An even stronger PSA suppression is reported for combined androgen blockade. In a study of 813 patients with advanced prostate cancer, 18 either bicalutamide 50 mg once daily or flutamide 250 mg three times daily, each in combination with an LHRH agonist, decreased PSA by 99% after three months.
In contrast to bicalutamide and leuprolide, the 5a reductase inhibitor finasteride seems to induce a more pronounced PSA suppression in men with BPH than in men with prostate cancer. 19 -21 Finasteride at a dosage of 5 mg once daily resulted in only 20 -30% PSA decrease and was clinically inefficient in the treatment of advanced prostate cancer, 19 whereas the drug resulted in a 50% decrease in PSA in BPH patients. 20, 21 The combination of flutamide 375 -750 mg and finasteride 5 mg daily suppressed mean PSA by 93% on average after 6 months in 21 patients with prostate cancer 22 and 750 mg flutamide and 10 mg finasteride daily resulted in a 97.6% reduction of PSA in 35 patients with advanced prostate cancer. 23 Overall, these data suggest that there is a different degree of androgen suppression of PSA originating from benign tissue versus cancer tissue, and that the direction of this discrepancy is different for various androgen suppressive regimens.
The bicalutamide and leuprolide studies had separate placebo groups, and were not designed for direct comparison between bicalutamide and leuprolide with regard to the extent of PSA suppression. Nevertheless, the two studies suggest that bicalutamide at a dosage of 50 mg daily causes a smaller PSA decline in BPH patients than (Figures 1 and  2 ). Based on studies of patients with prostate cancer 13 the standard dosage of bicalutamide monotherapy has later been increased to 150 mg daily. Our serum samples were stored at À20 C, and not the 770 to 780 C presently recommended for long-term storing prior to analysis of PSA. 24 This might result in a degradation of PSA and to low PSA values. However, PSA results for placebo patients were stable during the study period, irrespective of length of storage suggesting that the adverse effect of inadequate storing was negligible.
Acid phosphatase was unchanged during treatment with bicalutamide or leuprolide. ACP is produced in a variety of tissues (platelets, bone, etc.) in addition to the prostate. It is not surprising that this marker is relatively insensitive to androgen suppression.
Bicalutamide suppresses PAP in prostate cancer patients, 25 but corresponding data for BPH patients have not been reported previously. We found no change in PAP among patients receiving bicalutamide compared to placebo.
It has been suggested that PAP is insensitive to LHRH therapy in BPH patients. 7 We found a 43% decrease in PAP at week 12 and a 41% decrease at week 24 for patients receiving leuprolide (P < 0.005 at between group comparison).
Because of large interindividual differences in baseline levels and response to androgen suppression for the tumour markers studied, larger studies had been desirable. However, because of the occurrence of bothersome side effects compared to a modest clinical improvement of BPH symptoms for many of these patients, the studies were designed for a limited number of participants. Another weakness of the study was an excluison rate of 35% for the analysis of PSA results. However, patients were excluded for a variety of reasons (Tables 1 and 2) , and are not likely to affect the overall results.
